Bortezomib
Back to searchMolecule Structure
Scientific Name
Bortezomib
Description of the Drug
Bortezomib is a proteasome inhibitor used to treat multiple myeloma in patients who have not been successfully treated with at least two previous therapies.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB00188
http://www.drugbank.ca/drugs/DB00188
Brand Name(s)
Velcade
Company Owner(s)
Apotex Inc, Msn Laboratories Private Ltd, Fresenius Kabi Usa Llc, Teva Pharmaceuticals Usa Inc, Takeda Pharmaceuticals Usa Inc, Sandoz Inc, Pharmascience Inc, Jiangsu Hansoh Pharmaceutical Group Co Ltd, Hospira Inc, Kindos Pharmaceuticals Co Ltd
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
26S proteasome | PROTEIN COMPLEX | INHIBITOR | CHEMBL2364701 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL192129 | ||
Human Metabolome Database | HMDB0014334 | ||
DrugBank | DB00188 | ||
PubChem: Thomson Pharma | 14853748 | ||
PubChem | 387447 | ||
LINCS | LSM-6281 | ||
Nikkaji | J1.921.292K | ||
PDBe | BO2 | ||
BindingDB | 50069989 | ||
EPA CompTox Dashboard | DTXSID3040980 | ||
DrugCentral | 391 | ||
Brenda | 42093 | 16402 | 4725 |
Guide to Pharmacology | 6391 | ||
rxnorm | VELCADE | BORTEZOMIB | |
PubChem: Drugs of the Future | 12015194 | ||
ChEBI | 52717 | ||
ZINC | ZINC000169746649 |